StockIQ.techCSL Limited (CSL.AX) Stock Analysis
Free AI-powered analysis and research for CSL Limited stock
Sector: Healthcare
CSL.AX snapshot
Data as of 3 Nov 2026 close. Updated daily.
CSL Limited scores 53/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 96% of its 52-week range, up 13.3% over the past year. Latest reported figures show a profit margin of -16.3%, return on equity of -15.8% and revenue growth of +5.5%.
What is driving the score
- Strong Uptrend: +12
- MACD Bearish: -8
- Unprofitable (-16.3%): -15
- Strong Liquidity (2.21 Current Ratio): +8
- Negative ROE (-15.8%): -10
- Strong Long-term Uptrend: +8
- Up Over 1 Year (+13.3%): +3
- Near 52-Week High (96%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full CSL.AX report
CSL Limited (CSL.AX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze CSL.AX Now →📰 Latest Update
CSL (ASX:CSL) After New CEO Pick Still Looks Undervalued In The Leading Narrative
Sat, October 24, 2026 at 12:18 AM UTC 3 min read
CSL Limited (ASX: CSL) has appointed a new CEO, which has sparked discussions about the company's valuation in the current market. Analysts believe that despite the leadership change, CSL remains undervalued, presenting potential investment opportunities. This perspective is significant for investors as it suggests that the stock may offer growth potential as the company navigates its strategic direction under new management.